Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori

Table 1

Characteristics of RAK and RBAK therapies.

	RAK	RBAK	value
Patients (N)	81	81
Male/female (n)	35/46	40/41	0.43
Age (years, mean ± SD)	49.80 ± 14.4	51.16 ± 12.5	0.26
NSAIDs, n/N (%)	6/81 (7.4)	6/81 (7.4)	—
Prednisolone use, n/N (%)	1/81 (1.2)	1/81 (1.2)	—
Anticoagulant, n/N (%)	0/81 (0)	0/81 (0)	—
Smoke, n/N (%)	23/81 (28.4)	20/81 (24.7)	0.60
Alcohol, n/N (%)	10/81 (12.3)	6/81 (7.4)	0.29
Gastritis, n/N (%)	68/81 (84.0)	72/81 (88.9)	0.36
GU, n/N (%)	16/81 (19.8)	17/81 (21.0)	0.84
DU, n/N (%)	32/81 (39.5)	35/81 (43.2)	0.63
GU + DU, n/N (%)	4/81 (4.9)	12/81 (14.8)	0.04